



## **MicroTransponder CEO Will Rosellini to testify before the U.S. House of Representatives concerning Neurotechnology**

*SBIR program awards have funded neurotechnology research for TBI, Tinnitus, and PTSD resulting in potential new treatments for soldiers*

DALLAS, Texas – April 16, 2009 – MicroTransponder Inc., a privately held medical device company, announced today that CEO Will Rosellini has been invited by Chairwoman Nydia Velazquez of the U.S. House of Representatives Committee on Small Business to testify in a hearing entitled, “The Importance of Technology in an Economic Recovery” on April 22 at 1PM EDT. MicroTransponder is developing a wireless neurostimulation system for the treatment of chronic pain, TBI, Tinnitus, and PTSD.

“The SBIR program has enabled MicroTransponder to conduct important neuroscience research that was not fundable through traditional channels,” stated Will Rosellini, President and Chief Executive Officer. “We hope that the SBIR program is reauthorized at an increased level, as it is the driver of new innovation, which results in the creation of high tech companies with high quality jobs.” Rosellini added.

### **About MicroTransponder, Inc.**

MicroTransponder ( [www.microtransponder.com](http://www.microtransponder.com)) is developing a wireless neurostimulation system for the treatment of chronic pain and several other neurological indications. The minimally invasive device will provide relief from chronic pain without requiring an implanted battery or wires. The Company is finishing R&D on the device and accumulating data toward FDA clearance. MicroTransponder is also adapting our system for Vagus Nerve Stimulation to create a pipeline of innovative treatments for other neurological indications, including stroke rehabilitation, tinnitus, and autism.

Media Contact:

Jordan Curnes, COO

214-770-0935

Jordan@microtransponder.com